MARKET NEWS

Immunic Announces FDA Allowance of its Phase 2 Trial of COVID-19 Drug
CURE Announces Exercise of Warrants; Obtains Valuable Proprietary Formulation & Dosage Technology
Cresset & Inocardia to Develop In Silico Cardiac Safety Assay for Drug Candidate Screening
Rezolute Receives Rare Pediatric Disease Designation for Phase 2b Candidate
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial 
Arch Biopartners Submits IND Application to the FDA for Metablok (LSALT Peptide)

  FEATURED EDITORIAL

  COMPANY PROFILE

BioDuro is a leading global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery and development services, from lead development and IND-enabling studies to GMP manufacture of drug product for clinical trials. Core expertise includes small and large molecule discovery, development, and scale up, combined with unique technology platforms, such as bioavailability enhancement of insoluble compounds. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Melinta Therapeutics Enters Agreement to Acquire Tetraphase Pharmaceuticals

Melinta Therapeutics Enters Agreement to Acquire Tetraphase Pharmaceuticals

Melinta Therapeutics, Inc. recently announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. pursuant to which…

Relief Therapeutics & NeuroRx Expand Clinical Trial of COVID-19 Drug

Relief Therapeutics & NeuroRx Expand Clinical Trial of COVID-19 Drug

Relief Therapeutics  and its US partner, NeuroRx, Inc. recently announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with…

Vectura Signs License & Development Agreement With Aerami Therapeutics

Vectura Signs License & Development Agreement With Aerami Therapeutics

Vectura Group plc recently announced the signing of a global license and development agreement with Aerami Therapeutics Inc. for inhaled….

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

Ovid Therapeutics Inc. recently announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for……

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 24 – Controlled Release
July 8 – Prefilled Syringes